-
Britain, Rwanda in £100m court clash over migrant deal
-
'We will wait for each one': Ukrainians greet POWs with tears and cheers
-
UN watchdog says projectile struck Iran nuclear power plant
-
Trump faces impasse over Iran war
-
US Fed expected to hold rates steady as Iran war's shockwaves ripple
-
Former Australian Test wicketkeeper Haddin to coach NSW
-
China coach says team on right track despite Asian Cup heartache
-
Oscars audience drops, viewing figures show
-
Resilient Australia 'need to be better' in Women's Asian Cup final
-
Gio Reyna picked for US squad as Pochettino says World Cup roster still 'open'
-
Colombia, Ecuador leaders clash over bomb dropped near border
-
PSG, Real Madrid and Arsenal march into Champions League last eight
-
'Incomplete' Man City not what they once were, says Guardiola
-
US judge orders Trump admin to bring VOA employees back to work
-
White House pressure on Cuba mounts as island fights power cut
-
Arteta hails 'magical' Eze after Arsenal star sinks Leverkusen
-
Senegal stripped of AFCON title, Morocco declared champions
-
Nvidia says restarting production of China-bound chips
-
Real Madrid 'change' under Champions League spotlight: Vinicius
-
Real Madrid dump Man City out of Champions League once more
-
Clinical PSG bury Chelsea to reach Champions League quarter-finals
-
Eze rocket fires Arsenal into Champions League quarters
-
US airlines still see strong demand as jet fuel worries loom
-
Milei blasts Iran on anniversary of attack on Israeli embassy
-
USS Gerald R. Ford: the world's biggest aircraft carrier
-
US, European stocks rise despite latest jump in oil prices
-
Sporting Lisbon thrash Bodo/Glimt to reach Champions League quarters
-
Irish PM pushes Trump on Iran -- politely
-
Arizona charges prediction market Kalshi with illegal election betting
-
Leftist New York mayor under pressure on Irish unity question
-
Lebanon says Israeli strikes kill three soldiers
-
Atletico boss Simeone defends Spurs star Romero
-
Iran vets friendly ships for Hormuz passage: trackers
-
Iran women's football team arrive in Turkey on way home
-
Mexico prepared to host Iran World Cup games, says president
-
Trump blasts 'foolish' NATO on Iran, says US needs no help
-
Slot vows to win back support of frustrated Liverpool fans
-
In Ukraine, Sean Penn gifted Oscar made from train carriage hit by Russia
-
Ships in Gulf risk shortages on board, industry warns
-
White House piles pressure on Cuba as island fights power cut
-
Newcastle must grow under Camp Nou pressure: Howe
-
Trump says to make delayed China trip in 'five or six weeks'
-
Kompany warns of complacency as injury-hit Bayern host Atalanta
-
Larijani: Iran power player who rose then fell on winds of war
-
SAS cancels flights after fuel prices surge
-
New particle discovered by Large Hadron Collider
-
Lebanon says Israeli strikes kill soldiers, as shelters overflow
-
Van de Ven insists it's 'nonsense' to say players don't care about Spurs' plight
-
Argentina withdraws from World Health Organization
-
US Fed expected to keep rates steady as Iran war impact looms
Ketamine pill treats depression without psychedelic effects: study
A new pill that slowly releases ketamine could treat people with severe depression without giving them the psychedelic side effects of the often-misused drug, early trial results suggested on Monday.
First developed in the 1960s as an anaesthetic, ketamine's hallucinogenic and dissociative effects led to it becoming a party drug dubbed "Special K".
However, mounting research has demonstrated that ketamine is effective for the roughly quarter of people suffering from depression who see little benefit from common anti-depressant drugs.
In many countries, ketamine has been prescribed for depression for years.
US billionaire Elon Musk told CNN in March that he regularly uses a small amount of prescribed ketamine because it is "helpful for getting one out of the negative frame of mind".
The drug has long been administered intravenously in clinics, but more recently a nasal spray using a derivative called esketamine has increased in popularity.
Both can cause patients to have side effects such as dissociation, high blood pressure and an elevated heart rate.
There are also fears that medical use of the drug could slide into abuse.
The pill described in the journal Nature Medicine on Monday takes more than 10 hours to break down in the liver, lead study author Paul Glue told AFP.
"The really interesting feedback from patients is the lack of side effects -- no euphoria, no dissociation," said the researcher at New Zealand's University of Otago.
"I don't think these tablets would appeal to people who are abusing ketamine."
- Electro-shock alternative -
The phase 2 trial involved more than 270 people with depression who had previously tried an average of four different anti-depressant drugs.
More than half taking the ketamine pill went into remission for their depression, while 70 percent of the placebo group relapsed after 13 weeks, the study said.
Julaine Allan, an expert on mental health and addiction at Australia's Charles Sturt University who was not involved in the study, praised the trial while emphasising that more research is needed.
Ketamine does not work for everyone, and the "positive effects may wear off over time," she told AFP.
Michel Hoffmann, a psychiatrist at Geneva University Hospitals, said there is "real enthusiasm" in the medical community for ketamine's potential for treating depression.
"For patients who don't respond to conventional drugs, ketamine offers a way to avoid electro-shock therapy," he told AFP.
This last-resort treatment, which involves sending electric currents through the brain, has been proven to be effective.
But it can cause memory loss -- and some patients fear the procedure after seeing depictions of it in films such as "One Flew Over the Cuckoo's Nest".
- Fears of 'opioid style crisis' -
Some psychiatrists remain hesitant to prescribe ketamine for depression, fearing their patients could end up misusing the drug.
Last year, "Friends" actor Matthew Perry became the latest high-profile death from a ketamine overdose.
US police are investigating how Perry obtained the doses that caused his death -- he had reportedly not had a supervised infusion session for several days.
One potential benefit of quick-acting ketamine seen in previous research is that it could help patients considering suicide.
But there is "the plausible concern that the widespread use of ketamine might trigger a new opioid style crisis," Oxford researcher Riccardo De Giorgi said in a 2022 BMJ editorial.
By ridding ketamine of the side effects sought by some partygoers, the slow-release pill could alleviate some of these concerns.
There were still some side effects from the pill, the most common being headaches, dizziness and anxiety.
More research including phase 3 trials is needed before the drug can be reviewed by national medicine agencies, meaning it will be at least two or three years before patients could potentially access the pills, Glue said.
D.Schlegel--VB